Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Needham maintained its hold rating on Fate Therapeutics (NASDAQ:FATE) stock Thursday following the company’s presentation of updated clinical results for its FT819 therapy in lupus patients at the annual EULAR meeting in Spain. The stock, which has shown significant volatility with a 15.7% gain over the past week, currently trades at $1.55. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 8.81.
The early data showed encouraging signs, including one lupus nephritis patient in ongoing drug-free remission for more than a year, while other patients demonstrated improvements in various clinical measures of lupus, including the SLEDAI-2K assessment.
Despite these positive trends, Needham indicated it remains too early to determine FT819’s true clinical benefit due to the small sample size of only five patients and limited follow-up of three months or less in most participants. InvestingPro data shows the company faces financial challenges, with negative EBITDA of -$168.28M in the last twelve months, though it maintains more cash than debt on its balance sheet.
The research firm also noted that all patients in the study were under 30 years old, making the results difficult to contextualize for the broader lupus patient population.
Needham expects Fate Therapeutics to present a larger update with data from six to eight patients at the ACR conference in October, which could potentially serve as a catalyst for the company’s stock. With analyst price targets ranging from $2 to $12, investors seeking deeper insights can access comprehensive analysis and 13 additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Fate Therapeutics has reported significant developments in its FT819 cell therapy for systemic lupus erythematosus (SLE), including lupus nephritis. The company announced that all three patients with severe lupus nephritis treated with FT819 achieved a Primary Efficacy Renal Response. The therapy, which is currently in a Phase 1 clinical trial, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA to expedite its development and review. Additionally, Fate Therapeutics plans to expand the FT819 program to include other autoimmune conditions later in 2025. Analysts at BofA Securities and Baird have maintained Neutral ratings for the company, with BofA lowering its price target to $2.20 and Baird adjusting it to $4.00, citing competitive market conditions. Fate Therapeutics is set to present further data on FT819 at the European Congress of Rheumatology (EULAR 2025) in Barcelona. The company has approximately 450 cryopreserved drug product bags of FT819 available for patient treatment. Fate Therapeutics continues to explore additional clinical pathways and international expansion for its therapies, highlighting ongoing efforts to broaden the reach and impact of its cell therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.